Practice
Advisory work at the intersection of chemistry, programs, and decisions.
Engagements are scoped to a decision: whether a target is worth pursuing, whether a series can become a candidate, or whether a platform’s chemistry actually holds.
Drug discovery strategy
Target assessment, hit identification, hit-to-lead, lead optimization, candidate selection, and preclinical strategy.
- Go / no-go framing for early programs
- Progression criteria that chemistry and biology can share
- Portfolio prioritization for lean teams
Medicinal chemistry
Compound design, SAR analysis, synthetic feasibility, physicochemical property optimization, and ADME/DMPK interpretation.
- Design hypotheses that can actually be made
- Property and liability triage before the next analog cycle
- Synthetic strategy and troubleshooting
Computational drug discovery
Structure-based design, virtual screening, docking, FEP, ligand-based design, and AI/ML-enabled compound prioritization.
- Integrating modeling with medicinal-chemistry decisions
- Hit-finding campaigns that respect synthetic reality
- Prioritization that a chemist will stand behind
AI & scientific evaluation
Chemistry-domain LLM evaluation, prompt and task design, rubric development, scientific fact-checking, and model-output review.
- Benchmarking chemistry models against real discovery work
- SAR, mechanism, and feasibility review of generated output
- Practical limits of AI inside a live program
Pharmaceutical IP & technical support
Patent technical analysis, litigation support, composition-of-matter strategy, formulation/IP portfolio support, and scientific evidence review.
- Claim construction grounded in the chemistry
- Enablement, written description, and novelty questions
- Teaching materials for counsel and fact-finders
Scientific advisory & due diligence
Technology assessment, AI drug-discovery platform evaluation, scientific diligence, R&D strategy, and CRO/vendor review.
- Independent read on scientific robustness and differentiation
- Reproducibility and feasibility questions investors actually need
- Written diligence suitable for investment committees
Scientific advisory & R&D operations
Fractional leadership, laboratory strategy, technology implementation, external research management, and research infrastructure.
- Interim medicinal chemistry leadership for early teams
- CRO selection and external chemistry management
- Experimental priorities when resources are finite
Compound design & synthesis
Route planning, synthetic methodology, total synthesis, natural-product semi-synthesis, process feasibility, and mechanistic chemistry.
- Routes that survive scale and analog campaigns
- Process-chemistry feasibility before commitment
- Troubleshooting stalled synthetic sequences
Therapeutic areas
- Oncology
- Infectious disease
- CNS / neurology
- Metabolic disease
- Cardiovascular disease
- Psychiatric disorders
- Autoimmune disorders
Modalities
- Small molecules
- Natural products
- Targeted protein degraders
- Peptides
- Antibody-drug conjugates
Available for
Scientific advisory, fractional leadership, program review, AI evaluation, diligence, and pharmaceutical IP support.
Expert-network consultations are welcome when the question is chemical, not theatrical. I decline work I cannot stand behind.
Request a conversation